Search results
Results From The WOW.Com Content Network
Moderna Inc (NASDAQ: MRNA) is trading lower Monday morning after the U.S. Food and Drug Administration delayed approval of the company's Emergency Use Authorization request for the use of its ...
Moderna's operations burned through $2.7 billion during the 12 months that ended last September, but the company is finally getting a handle on operating expenses that declined significantly in 2024.
In the presentation slides to the U.S. agency, Moderna Inc (NASDAQ:MRNA) shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up.
Full map including municipalities State, territorial, tribal, and local governments responded to the COVID-19 pandemic in the United States with various declarations of emergency , closure of schools and public meeting places, lockdowns , and other restrictions intended to slow the progression of the virus.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
Moderna expects to be operating cash flow breakeven in 2028 with revenue of $6 billion. It said its balance sheet was sufficient to fund its current R&D investments without having to raise capital.